FrancophonIA/ELRC3.0 huggingface dataset:
English: • Ph+ acute lymphoblastic leukaemia (ALL), a type of cancer in which lymphocytes (another type of white blood cell) multiply too quickly.
Estonian: • Philadelphia-kromosoom-positiivne akuutne lümfoblastne leukeemia (Ph+ ALL) - vähivorm, kus lümfotsüüdid (teatud leukotsüüdid) paljunevad liiga kiiresti.
English: What is Glivec used for?
Estonian: Milleks Glivecit kasutatakse?
English: • dermatofibrosarcoma protuberans (DFSP), a type of cancer (sarcoma) in which cells in the tissue beneath the skin divide uncontrollably.
Estonian: • Protuberantne dermatofibrosarkoom (DFSP) - vähiliik (sarkoom), kus nahaaluse koe rakud vohavad.
English: This study measured how long the patients lived without their cancer getting worse.
Estonian: Uuringus jälgiti patsientide elulemust vähi süvenemiseni.
English: Glivec is used to treat adults with HES or CEL who have a specific re-arrangement of two genes called FIP1L1 and PDGFRα;
Estonian: Glivecit kasutatakse kaugelearenenud hüpereosinofiilse sündroomi või kroonilise eosinofiilleukeemiaga täiskasvanute ravimiseks, kellel on kaks geeni (FIP1L1 ja PDGFRα) teataval viisil muundunud.
English: Glivec is used to treat adults with GIST that cannot be removed with surgery or have spread to other parts of the body, and adults who are at risk of GIST coming back after surgical removal;
Estonian: Glivecit kasutatakse gastrointestinaalse stromaaltuumoriga täiskasvanute raviks, kui tuumorit ei saa kirurgiliselt eemaldada, kui vähk on siiretega (levinud organismis mujale) või kui täiskasvanud patsientidel on gastrointestinaalse stromaaltuumori taastumise oht pärast selle kirurgilist eemaldamist.
English: • gastrointestinal stromal tumours (GIST), a type of cancer (sarcoma) of the stomach and bowel, when there is uncontrolled growth of cells in the supporting tissues of these organs.
Estonian: • Gastrointestinaalne stromaaltuumor (GIST) - mao- ja soolevähi liik (sarkoom), kus nende elundite tugikudede rakud vohavad.
English: Glivec is used in combination with other anticancer medicines in adults and children who have been newly diagnosed with Ph+ ALL.
Estonian: Glivecit kasutatakse koos teiste vähiravimitega täiskasvanute ja laste raviks, kellel on äsja diagnoositud Philadelphia-kromosoompositiivne akuutne lümfoblastne leukeemia (Ph+ ALL).
English: Glivec is used to treat adults with MD/MPD who have re-arrangements of the gene for platelet-derived growth factor receptor (PDGFR);
Estonian: Glivecit kasutatakse müelodüsplastiliste või müeloproliferatiivsete haigustega täiskasvanute ravimiseks, kellel on trombotsüütide kasvuteguri retseptori (PDGFR) geen muundunud.
English: Glivec is used when the patients are ‘Philadelphia chromosome positive' (Ph+).
Estonian: Ravimit kasutatakse Philadelphia-kromosoom-positiivsetel (Ph+) patsientidel ehk patsientidel, kelle osa geene on ümber korraldunud nn Philadelphia kromosoomiks.
English: How has Glivec been studied?
Estonian: Kuidas Glivecit uuriti?
English: The medicine can only be obtained with a prescription.
Estonian: Glivec on retseptiravim.
English: In both studies, the majority of patients were adults.
Estonian: Mõlemas uuringus oli enamik patsiente täiskasvanud.
English: Systemic formulations of levofloxacin (such as tablets and solutions for infusion) have been authorised in the EU since the 1990s.
Estonian: Levofloksatsiini süsteemsed ravimvormid (nagu tabletid ja infusioonilahused) on ELis olnud lubatud alates 1990. aastatest.
English: What measures are being taken to ensure the safe and effective use of Quinsair?
Estonian: Mis meetmed võetakse, et tagada Quinsairi ohutu ja efektiivne kasutamine?
English: A risk management plan has been developed to ensure that Quinsair is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Quinsairi võimalikult ohutu kasutamine.
English: Treatment cycles may be repeated for as long as the patient benefits.
Estonian: Ravitsükleid tohib korrata seni, kuni sellest on patsiendile kasu.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Quinsair on 26 March 2015.
Estonian: Euroopa Komisjon andis Quinsairi müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 26. märtsil
English: Other information about Quinsair
Estonian: Muu teave Quinsairi kohta
English: Before using Quinsair, doctors should consider official guidance on the appropriate use of antibiotics.
Estonian: Enne Quinsairi kasutamist peab arst arvesse võtma antibiootikumide asjakohase kasutamise ametlikke juhiseid.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Quinsair's benefits are greater than its risks and recommended that it be approved for use in the EU.
Estonian: Inimravimite komitee otsustas, et Quinsairi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: The most common side effects with Quinsair are cough (seen in 54% of patients), dysgeusia (taste disturbances, 30%) and tiredness/weakness (25%).
Estonian: Quinsairi kõige tavalisemad kõrvalnähud on köha (esines 54% patsientidest), düsgeusia (maitsehäire, 30%) ja väsimus/nõrkus (25%).
English: Because levofloxacin has a potential risk on cartilage, the use of the product was not considered justified in adolescents.
Estonian: Kuna levofloksatsiiniga kaasneb võimalik risk kõhredele, ei soovitata ravimit kasutada noorukitel.
English: In addition, the company that markets Quinsair will carry out a study to investigate the long-term safety of Quinsair when used in clinical practice in the European Union.
Estonian: Lisaks teeb Quinsairi turustav ettevõte uuringu Quinsairi pikaajalise ohutuse uurimiseks Quinsairi kasutamisel kliinilises praktikas Euroopa Liidus.
English: Following 28 days of treatment, the patients taking Quinsair had an improvement in FEV1 of 1.73%, while for patients taking placebo the improvement in FEV1 was of around 0.43%.
Estonian: Pärast 28päevast ravi oli Quinsairi võtnud patsientide FEV1 paranenud 1,73%, samas kui platseebot võtnud patsientide FEV1 oli paranenud ligikaudu 0,43%.
English: What is Quinsair and what is it used for?
Estonian: Mis on Quinsair ja milleks seda kasutatakse?
English: The first study, which involved 330 patients, compared Quinsair with placebo (a dummy treatment), while the second, involving 282 patients, compared it with another inhaled antibiotic (tobramycin).
Estonian: Esimeses uuringus, kus osales 330 patsienti, võrreldi Quinsairi platseeboga (näiva ravimiga) ning teises uuringus, kus osales 282 patsienti, võrreldi seda teise inhaleeritava antibiootikumiga (tobramütsiiniga).
English: This is a summary of the European public assessment report (EPAR) for Quinsair.
Estonian: See on ravimi Quinsair Euroopa avaliku hindamisaruande kokkuvõte.
English: Regarding safety, Quinsair was well tolerated with side effects similar to those of levofloxacin given systemically (throughout the body).
Estonian: Ohutuse poolest on Quinsair hästi talutav ja selle kõrvalnähud sarnanevad süsteemselt (kogu kehas) manustatava levofloksatsiini kõrvalnähtudega.
English: Why is Quinsair approved?
Estonian: Miks Quinsair heaks kiideti?
English: What are the risks associated with Quinsair?
Estonian: Mis riskid Quinsairiga kaasnevad?
English: It works by blocking enzymes that P. aeruginosa bacteria use to make copies of their DNA during cell multiplication.
Estonian: Selle toimel blokeeritakse ensüümid, mida P. aeruginosa bakterid kasutavad rakujagunemisel oma DNA kopeerimiseks.
English: It is not intended to provide practical advice on how to use Quinsair.
Estonian: Hindamisaruandes ei anta Quinsairi kasutamise praktilisi nõuandeid.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Quinsair, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Quinsairi omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: For practical information about using Quinsair, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Quinsairi kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: Cystic fibrosis is an inherited disease in which there is an accumulation of thick mucus in the lungs that allows bacteria to grow more easily, causing infections.
Estonian: Tsüstiline fibroos on pärilik haigus, mille korral koguneb kopsu paks lima, mis soodustab bakterite kasvu, põhjustades infektsioone.
English: The CHMP considered that the modest improvement in FEV1 seen with Quinsair meant that it could help to meet the need for additional inhaled antibiotics to treat long-term P. aeruginosa infections in cystic fibrosis.
Estonian: Inimravimite komitee arvates tähendas Quinsairiga ravimisel täheldatud mõõdukas FEV1 paranemine, et selle ravimiga saab rahuldada vajadust inhaleeritavate lisaantibiootikumide järele, millega ravida tsüstilise fibroosi korral tekkivaid pikaajalisi P. aeruginosa infektsioone.
English: The second study showed that Quinsair was at least as good as tobramycin at improving FEV1 following 1 to 3 treatment cycles.
Estonian: Teisest uuringust nähtus, et Quinsair on FEV1 parandamisel pärast 1 kuni 3 ravitsüklit vähemalt sama hea kui tobramütsiin.
English: It must not be used in pregnant or breastfeeding women.
Estonian: Quinsairi ei tohi kasutada raseduse ja imetamise ajal.
English: For the full list of all side effects reported with Quinsair, see the package leaflet.
Estonian: Quinsairi kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: The full EPAR and risk management plan summary for Quinsair can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst ja riskijuhtimiskava kokkuvõte Quinsairi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports Kui vajate Quinsairiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: By doing this, it stops the bacteria that are causing the infection from growing and multiplying.
Estonian: Sellega peatatakse nakkust põhjustavate bakterite kasvamine ja paljunemine.
English: How does Quinsair work?
Estonian: Kuidas Quinsair toimib?
English: Quinsair has been investigated in two main studies in patients who had cystic fibrosis with P. aeruginosa lung infection.
Estonian: Quinsairi uuriti kahes põhiuuringus tsüstilise fibroosi ja P. aeruginosa põhjustatud kopsuinfektsiooniga patsientidel.
English: However, the study failed to show that Quinsair is more effective than placebo at increasing the time it took before the patients had an exacerbation (flare-up) of their disease.
Estonian: Uuringust aga ei nähtunud, et Quinsair oleks platseebost efektiivsem patsientide haiguse ägenemiseni kulunud aja pikendamisel.
English: Quinsair is an antibiotic used for treating long-term lung infection caused by the bacteria Pseudomonas aeruginosa in adults who have cystic fibrosis.
Estonian: Quinsair on antibiootikum, mida kasutatakse bakteri Pseudomonas aeruginosa põhjustatud kroonilise kopsuinfektsiooni raviks tsüstilise fibroosiga täiskasvanud patsientidel.
English: What benefits of Quinsair have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Quinsairi kasulikkus?
English: Quinsair contains the active substance levofloxacin.
Estonian: Quinsair sisaldab toimeainena levofloksatsiini.
English: Quinsair is inhaled using a device called Zirela nebuliser system, which converts the solution in the ampoule into a fine mist.
Estonian: Quinsairi inhaleeritakse Zirela nebulisaatoriga, mis muudab ampullis oleva lahuse peeneks uduks.
English: Quinsair must not be used in patients with epilepsy and those with a history of tendon disorders related to the use of fluoroquinolone antibiotics.
Estonian: Quinsairi ei tohi kasutada epilepsiaga patsientidel ja patsientidel, kellel on anamneesis fluorokinoloonantibiootikumidega seotud kõõlusekahjustus.
English: In the first study, Quinsair was shown to be better than placebo at improving the patients' forced expiratory volume in one second (FEV1), adjusted for the patient's age, height and sex. FEV1 is the most air a person can breathe out in one second.
Estonian: Esimeses uuringus osutus Quinsair patsientide forsseeritud ekspiratoorse sekundimahu (FEV1) parandamisel platseebost paremaks, kusjuures FEV1 kohandati vastavalt patsiendi vanusele, kasvule ja soole.
English: The active substance in Quinsair, levofloxacin, belongs to the group of antibiotics known as ‘fluoroquinolones'.
Estonian: Quinsairi toimeaine levofloksatsiin kuulub fluorokinoloon-antibiootikumide rühma.
English: How is Quinsair used?
Estonian: Kuidas Quinsairi kasutatakse?
English: Quinsair is available as a nebuliser solution in single-dose containers called ‘ampoules'.
Estonian: Quinsairi turustatakse nebuliseeritava lahusena üheannuselistes ampullides.
English: Quinsair levofloxacin
Estonian: Quinsair levofloksatsiin
English: Levofloxacin is a well-known antibiotic.
Estonian: Levofloksatsiin on tuntud antibiootikum.
English: Ref.: EMEA/CHMP/730064/2009
Estonian: London, 19. november 2009 Viide: EMA/730064/2009 EMEA/H/C/997
English: What is Gemesis?
Estonian: Mis on Gemesis?
English: The main measure of effectiveness was the change in ‘clinical attachment level' (CAL) after 24 weeks.
Estonian: Efektiivsuse põhinäitaja oli muutus kliinilise kinnitumise tasemes (CAL) 24 nädala järel.
English: After considering the grounds for this request, the CHMP re-examined the initial opinion, and confirmed the refusal of the marketing authorisation on 19 November 2009.
Estonian: Pärast taotluse põhjenduste kaalumist vaatas komitee oma algse arvamuse taas läbi ja kinnitas 19. novembril 2009 antud soovitust müügiloa andmisest keelduda.
English: The company that applied for authorisation is BioMimetic Therapeutics Ltd.
Estonian: Müügiluba taotles BioMimetic Therapeutics Ltd.
English: Gemesis is a kit for implant.
Estonian: Gemesis on implantaadi valmistamise komplekt.
English: The CHMP noted that the company did not at this time have sufficient information on how strongly becaplermin binds to PDGF receptors and did not sufficiently demonstrate that Gemesis used in clinical studies was comparable to the product intended to be placed on the market.
Estonian: Inimravimite komitee märkis, et ettevõttel ei olnud sel ajal piisavalt teavet selle kohta, kui tugevasti seondub bekaplermiin PDGF-i retseptoritega, ega tõendatud piisavalt, et kliinilistes uuringutes kasutatud Gemesis oli võrreldav ravimiga, mida kavatseti hakata turustama.
English: Growth factors are proteins that stimulate cells to multiply.
Estonian: Kasvutegurid on valgud, mis stimuleerivad rakkude paljunemist.
English: In one main study involving 180 adults with advanced periodontal disease, Gemesis was compared with the matrix alone.
Estonian: Ühes põhiuuringus, milles osales 180 täiskasvanut, kellel oli kaugelearenenud parodondi haigus, võrreldi Gemesise kasutamist ainult maatriksi kasutamisega.
English: The kit consists of a prefilled syringe containing the active substance becaplermin and a cup containing granules of β-tricalcium phosphate to be used as a matrix.
Estonian: Komplekt koosneb eeltäidetud süstlast, mis sisaldab toimeainet bekaplermiini, ja topsist, mis sisaldab maatriksina kasutatavat β-trikaltsiumfosfaadi graanuleid.
English: On 23 July 2009, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product Gemesis, intended for bone and periodontal (around the teeth) regeneration in adults.
Estonian: 23. juulil 2009 võttis inimravimikomitee vastu negatiivse otsuse, soovitades täiskasvanute luu ja parodondi regeneratsiooni raviks kasutava ravimi Gemesise müügiloa andmisest keelduda.
English: Gemesis was expected to be used to regenerate tissue in adults with defects around the teeth, including defects within the surrounding bone and receding gums.
Estonian: Gemesist kavatseti kasutada täiskasvanutel, et regenereerida hambaid ümbritsevat defektidega kude, sh luude defekte ja taanduvat igeme kude.
English: Becaplermin is produced by a method known as ‘recombinant DNA technology': it is made by a cell that has received a gene (DNA), which makes it able to produce human platelet-derived growth factor.
Estonian: Bekaplermiini valmistatakse rekombinant-DNA-tehnika abil: seda toodab rakk, millele on lisatud inimese PDGF-kasvufaktori teket võimaldav geen (DNA).
English: What are the consequences of the refusal for patients in clinical trials or compassionate use programmes using Gemesis?
Estonian: Kuidas mõjutab tagasivõtmine praegu Gemesise kliinilistes uuringutes või eriloaga kasutamise programmides osalevaid patsiente?
English: The CHMP was of the opinion that the main study failed to show that Gemesis was effective in treating periodontal defects.
Estonian: Inimravimite komitee arvas, et põhiuuringu tulemused ei näidanud Gemesise efektiivsust parodondi defektide ravis.
English: The company informed the CHMP that there are no patients in clinical trials or compassionate use programmes using Gemesis.
Estonian: Ettevõte teatas inimravimite komiteele, et Gemesise kliinilistes uuringutes või eriloaga kasutamise programmides patsiente ei osale.
English: Becaplermin was expected to work in the same way as human platelet-derived growth factor, stimulating cell growth in the bone and gums around the teeth and helping tissue to heal.
Estonian: Bekaplermiin pidi eeldatavalt toimima samamoodi kui looduslik kasvutegur, stimuleerides luu- ja igemekoe rakkude kasvu ning soodustades koe paranemist.
English: What was Gemesis expected to be used for?
Estonian: Milleks kavatseti Gemesist kasutada?
English: The active substance in Gemesis, becaplermin, is a recombinant human platelet-derived growth factor (PDGF).
Estonian: Gemesise toimeaine bekaplermiin on inimvalgu trombotsüütidest pärinev rekombinantne kasvutegur (PDGF).
English: Questions and answers on the recommendation for the refusal of the marketing authorisation for Gemesis
Estonian: Müügiloa andmisest keeldumise soovituse teave Gemesis bekaplermiin
English: Therefore, at that point in time, the CHMP was of the opinion that the benefits of Gemesis did not outweigh its risks.
Estonian: Seetõttu oli inimravimite komitee müügiloa taotluse tagasivõtmise ajal arvamusel, et Gemesise kasulikkus ei ole suurem kui kaasnevad riskid.
English: CAL is a measure of the loss of support to the teeth from surrounding tissue.
Estonian: Kliinilise kinnitumise tase näitab, mil määral toetab ümbritsev kude hambaid.
English: Hence, the CHMP recommended that Gemesis be refused marketing authorisation.
Estonian: Nii soovitas inimtervishoius kasutatavate ravimite komitee keelduda Gemesise müügiloa andmisest.
English: Gemesis was to be prepared by mixing the solution containing becaplermin with the matrix, which was then to be placed into the defect around the teeth to promote healing.
Estonian: Gemesise valmistamiseks tuli segada bekaplermiini sisaldav lahus maatriksiga ja seejärel kanda maatriks hamba ümbruse defektidele, et soodustada paranemist.
English: Platelet-derived growth factors act on cells that are involved in wound repair.
Estonian: Trombotsüütidest (vereliistakutest) pärinevad kasvutegurid mõjuvad haavade paranemisega seotud rakkudele.
English: The effects of Gemesis were first tested in experimental models before being studied in humans.
Estonian: Enne inimuuringuid kontrolliti Gemesise toimet muude katsetega.
English: The CHMP was also concerned about the level of product-related impurities present.
Estonian: Inimravimite komiteed tegi ka ettevaatlikuks ravimi tootmislisandite sisaldus.
English: 300 mg Powder for concentrate for solution for infusion
Estonian: 300 mg infusioonilahuse kontsentraadi pulber
English: Do not pass it on to anyone else.
Estonian: Ärge andke seda kellelegi teisele.
English: MARKETING AUTHORISATION NUMBER(S) EU/1/98/093/002
Estonian: MÜÜGILOA NUMBER(NUMBRID) EU/1/98/093/002
English: Other possible but less frequent undesirable effects are:
Estonian: Teised võimalikud, kuid harvem esinevad kõrvaltoimed on:
English: if you have hypocalcaemia.
Estonian: kui teil on hüpokaltseemia.
English: Serious allergic reactions will need emergency treatment.
Estonian: Tõsised allergilised reaktsioonid vajavad erakorralist ravi.
English: Frequency categories:
Estonian: Esinemissageduse kategooriad:
English: Driving and using machines:
Estonian: Autojuhtimine ja masinatega töötamine:
English: • metallic taste in the mouth
Estonian: • metalli maitse suus
English: Very common ( >1/10); common (>1/100, <1/10); uncommon (>1/1,000, < 1/100); rare (>1/10,000, < 1/1,000); very rare (<1/10,000), including isolated reports.
Estonian: Väga sage ( >1/10); sage (>1/100, <1/10); aeg-ajalt (>1/1000, < 1/100); harv (>1/10000, < 1/1000); väga harv (<1/10000), sealhulgas üksikjuhud.
English: Please ask him to explain the reasons for any changes in your treatment schedule.
Estonian: Palun laske tal selgitada kõigi raviskeemis tehtavate muudatuste põhjuseid.
English: This medicine has been prescribed for you personally and you should not pass it on to others.
Estonian: Ravim on välja kirjutatud isiklikult teile ja seda ei tohi anda kellelegi teisele.
English: An antiemetic may be administered, if required.
Estonian: Vajadusel võib manustada antiemeetikumi.
English: The solution is clear, colourless and sterile.
Estonian: Lahus on selge, värvusetu ja steriilne.
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorization: 11-01-1999
Estonian: ESMASE MÜÜGILOA VÄLJASTAMISE/MÜÜGILOA UUENDAMISE KUUPÄEV Esmase müügiloa väljastamise kuupäev: 11.01.1999
English: 174 56 Alimos, Athens, Greece.
Estonian: 174 56 Alimos, Athens, Kreeka
English: Your doctor may then decide that it is not safe for you to receive this medicine.
Estonian: Arst võib siis otsustada, et teie jaoks pole selle ravimi kasutamine ohutu.
English: Bioavailability following subcutaneous and intramuscular injection in humans is high and similar for the two routes of administration (71% and 66%, respectively).
Estonian: Subkutaanse ja intramuskulaarse süste järgne biosaadavus inimestel on kõrge ja nende kahe manustamistee puhul sarnane (vastavalt 71% ja 66%).
English: In some cases, however, your doctor may decide to use another dose or another frequency of dosing.
Estonian: Mõnedel juhtudel võib teie arst siiski otsustada kasutada teistsugust annust või annustamise sagedust.
English: • swelling of the tongue or throat
Estonian: • keele või kõri turse
English: Never change the dose yourself or stop injecting the medicine without consulting your doctor first.
Estonian: Ärge kunagi muutke ise oma annust ega lõpetage ravimi süstimist ilma eelnevalt oma arstiga nõu pidamata.
English: If you forget to inject your medicine at the correct time, inject it as soon as you remember unless it is almost time for the next dose.
Estonian: Kui unustasite õigel ajal ravimit süstida, süstige see niipea, kui see teile meenub, va juhul, kui peaaegu on käes aeg järgmiseks annuseks.
English: Each pack contains 10 ampoules.
Estonian: Iga pakend sisaldab 10 ampulli.
English: The treatment should be maintained until patients are fully mobilized.
Estonian: Ravi tuleb jätkata, kuni patsientide liikumisvõime on täielikult taastunud.
English: Any product where such defects are observed should be discarded.
Estonian: Toode, mille juures esineb selliseid puudusi, tuleb ära visata.
English: Using FORCALTONIN with other medicines:
Estonian: FORCALTONIN'i kasutamine koos teiste ravimitega:
English: Such allergic reactions have only been seen in a very few cases and the most extreme form, anaphylactic shock, is very rare.
Estonian: Sellised allergilised reaktsioonid on ilmnenud väga vähestel juhtudel ja kõige ekstreemsem vorm, anafülaktiline šokk, esineb väga harva.